CD19+ RELAPSE/REFRACTORY B-ALL

Clinical trials for CD19+ RELAPSE/REFRACTORY B-ALL explained in plain language.

Never miss a new study

Get alerted when new CD19+ RELAPSE/REFRACTORY B-ALL trials appear

Sign up with your email to follow new studies for CD19+ RELAPSE/REFRACTORY B-ALL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New cell therapy tested for tough blood cancers

Disease control Not yet recruiting

This early study aims to find a safe dose of an experimental cell therapy called LV009 for adults whose CD19-positive blood cancers have returned or not responded to standard treatments. Researchers will give LV009 to up to 19 participants and closely monitor them for side effect…

Matched conditions: CD19+ RELAPSE/REFRACTORY B-ALL

Phase: EARLY_PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control

Last updated Mar 30, 2026 14:30 UTC

CD19+ RELAPSE/REFRACTORY B-ALL

Get alerted when new CD19+ RELAPSE/REFRACTORY B-ALL trials appear

New cell therapy tested for tough blood cancers